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Abstract 
Objectives: The aim of this prospective study was to assess the influence of different 
normalisation procedures on relative changes in standardised uptake values (SUV) of FDG-
PET for the assessment of chemotherapy response in patients with colorectal carcinoma 
(CRC) and non-small cell lung carcinoma (NSCLC). Methods: In 97 patients with CRC 5 
(n=48) and NSCLC (n=49) FDG-PET was performed before and during the course of 
chemotherapy. Relative changes in SUV (ΔSUV) were determined after correction for 
injected dose and bodyweight, lean body mass, body surface area or a combination of 
bodyweight and plasma glucose. The predictive value for overall (OS) and progression free 
survival (PFS) with respect to the different normalised ΔSUVs was assessed. Results: In 10 
both CRC and NSCLC no differences were seen in the degree of change between the four 
SUV-normalisations during chemotherapy. Cox regression analysis for OS showed 
significant hazard ratios of 1.14-1.16 per ten percent SUV-change in CRC and 1.10-1.13 in 
NSCLC and for PFS hazard ratios of 1.15 per ten percent ΔSUV-change in CRC and 1.10-
1.12 in NSCLC. Conclusions: Relative change of SUV is a strong predictor for survival in 15 
both CRC and NSCLC. None of the four normalisation methods showed statistical 
advantage over the other. Therefore, simplifying the methods for analysis of FDG-PET data 
can improve the incorporation of FDG-PET in clinical treatment-response monitoring and 
may facilitate application in multicentre trials. 
 20 
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Introduction 25 
Functional imaging by 18F-2-fluoro-2-deoxy-D-glucose positron emission tomography 
(FDG-PET) has an established role in the standard care of patients with both colorectal 
carcinoma (CRC) and non-small cell lung carcinoma (NSCLC). Interest in the application 
of FDG-PET for prediction and evaluation of tumour response to therapy is growing. When 
using morphological imaging techniques such as computed tomography (CT) or magnetic 30 
resonance imaging (MRI) it may be difficult to reliably distinguish between necrosis, scar 
tissue and recurrent or residual tumour in CRC [1-3] and NSCLC [4]. Furthermore, 
metabolic alterations in tumour cells, indicative of tumour response to therapy, may arise 
earlier than changes in size [5]. Moreover, some new antitumour therapies are cytostatic 
rather than cytoreductive. Therefore success of treatment cannot reliably be measured on 35 
morphologic imaging modalities alone. Early detection of tumour progression during 
chemotherapy can prevent unbeneficial and potentially harmful treatment and provides the 
opportunity to modify treatment at an early treatment stage. 
In CRC [6] as well as NSCLC [7-9] a significant prognostic value for overall 
survival (OS) and progression-free survival (PFS) by (semi)quantitative measures of FDG-40 
PET data analysis has been shown. Also, the response to chemotherapy, evaluated as 
relative change in FDG-PET-assessed tumour metabolism in CRC [10,11] and NSCLC 
[9,12], proved to be significantly associated with OS and PFS. In these studies it was 
suggested that less demanding semi-quantitative parameters such as the standardised uptake 
value (SUV) might perform as well as complex dynamic imaging protocols necessary for 45 
Patlak analysis [11,13] which would facilitate broad introduction in clinical practice by 
improving patient compliance. Another advantage of the SUV is that it can be calculated 
from static, whole-body FDG-PET studies, which depict all metastases. In quantitative 
dynamic scans only one axial field of view (15-20cm) can be studied which could exclude 
metastases which respond differently to therapy [11]. 50 
The present study aims at further standardisation, validation and simplification of the 
methods necessary for metabolic response assessment. For this purpose four distinct 
normalisation methods for relative changes in SUV (ΔSUV) were evaluated in two patient 
populations (CRC and NSCLC). SUVs were determined from scans performed on one bed 
position only, since this study was part of a larger project, which included dynamic 55 
acquisition. This single axial field of view was chosen to include as many lesions as 
possible, based on the baseline whole-body staging FDG-PET, acquired at an earlier time 
point. 
. Overall and progression free survival were used as outcome measures. For 
absolute SUV measurement the different normalisation procedures are already extensively 60 
compared in former studies [14], of which some seem superior to others [13,15] when 
compared to full parameter pharmacokinetics by nonlinear regression. These studies, 
however, address the prognostic value of SUV by its absolute value. In contrast, in the 
present study, the relative value will be examined, which is of importance in therapy 
response monitoring.65 
 Patients and methods 
Patient eligibility criteria 
Patients eligible for the FDG-PET chemotherapy response monitoring studies on CRC [11] 
and NSCLC [12] were included in the present study. In all patients, treatment decisions 70 
were based on current guidelines and made by a multidisciplinary team including medical 
oncologists, oncological and cardio-thoracic surgeons, pulmonologists, radiation 
oncologists, pathologists, radiologists and nuclear medicine physicians. All clinicians were 
blinded to the results of the FDG-PET scans. The study was approved by the Institutional 
Review Board of the Radboud University Nijmegen Medical Centre and written informed 75 
consent was obtained from each patient. 
 
FDG-PET 
FDG-PET was performed at baseline and after two months of treatment (CRC) or after the 
second or third cycle of chemotherapy (NSCLC), depending on the chemotherapy regimen. 80 
Patients were fasted for at least 6h before imaging. Intake of sugar-free liquids was 
permitted. A dose of ~200MBq FDG (Covidien, Petten, the Netherlands) was injected 
intravenously. All scans were acquired between 40 and 50 minutes post injection on an 
ECAT-EXACT47 FDG-PET scanner (Siemens/CTI, TN, USA) in septa-extended (2-
dimensional) mode. The position of the patient in the scanner’s field of view (162mm in 47 85 
planes) was based on whole-body FDG-PET and CT scans performed for routine clinical 
work-up, including as many measurable tumour lesions as possible. Only one field of view 
was scanned, since this study was part of a larger project, which included dynamic scanning 
[11,12]. A 20-min transmission scan was performed, using the internal 68Ge/68Ga sources, 
to correct for photon attenuation, the duration of which was chosen to provide a higher 90 
signal-to-noise ratio. The emission and transmission sinograms were corrected for randoms 
and decay. Scatter correction based on measured scatter fractions as implemented in the 
ECAT 7.2.1. software for 2D reconstructions was used. Attenuation-corrected images were 
reconstructed in 128x128x47 matrices using filtered backprojection with a Gaussian filter 
of 4 mm full width at half maximum (FWHM). This resulted in voxels of 3.432mm x 95 
3.432mm x 3.375mm and a spatial resolution of 6mm FWHM in the reconstructed images. 
FDG-PET scans were evaluated semi-quantitatively by standardised uptake value 
(SUV) analysis. Tumour regions of interest (ROI) were obtained semi-automatically using 
a threshold of 50% of the maximum pixel value within the lesion. Four different SUVs, 
based on injected dose and bodyweight (SUVBW), lean body mass (SUVLBM), body surface 100 
area (SUVBSA) and a combination of bodyweight and plasma glucose (SUVBW+G) were 
calculated (table 1) [14]. The injected dose was calculated by subtraction of the residual 
18F-activity of the infusion system from the 18F-activity delivered by the laboratory, 
corrected for decay to time of injection: )()( )()( θλτλ −⋅−−⋅− ⋅−⋅= tt eRDeDDID  where DD is 
the delivered dose, RD is the residual dose, λ is the decay constant of 18F (=0.006314 min-105 
1), (t-τ) is the time interval between delivery and injection and (t-θ) is the (negative) time 
interval between activity measurement of the infusion system and injection. 
When multiple lesions were quantified in one patient, a patient’s mean SUV was 
calculated weighting every lesion by its volume by the formula: 
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The relative change in SUV (ΔSUV) between the baseline and second FDG-PET 
was calculated (ΔSUV=[SUVfollow-up-SUVbaseline]·SUVbaseline-1·100%). All lesions which 
were completely visible in the FoV were included. There was no maximum to the number 
of lesions per patient. 
115 
 
Clinical Follow-Up 
During and after treatment, patients were followed-up with clinical- and radiological 
examination and laboratory tests at regular intervals. Morphologic tumour response was 
routinely evaluated according to Response Evaluation Criteria in Solid Tumours (RECIST) 120 
[16] without knowledge of the results of the FDG-PET studies. These criteria define 
progression as a 20% increase in the sum of longest diameters of target lesions or the 
appearance of new lesion [16]. When disease progression was suspected or proven, patients 
were always restaged by the previously mentioned multidisciplinary team. The date of local 
or distant progression was defined as the earliest date at which disease progression was 125 
confirmed, either clinically or by imaging or biopsy. 
In patients who were progression free at the closeout date (April 2008) or who had 
died from any non-tumour related cause, the time to progression was censored at that date. 
Overall survival was measured from the date of the baseline FDG-PET scan to the date of 
death. In patients who were alive at the closeout date, survival was censored at that date. 130 
 
Statistical Analysis 
Normality of the data was assessed by the Shapiro-Wilk statistic. For normal distributions 
mean (±standard deviation) are presented and the paired t-test was used for comparison. For 
non-normal distributions, median (interquartile range, IQR) are presented as measures for 135 
central tendency and dispersion and the Wilcoxon signed ranks test was used for 
comparison. Comparing medians between dependent groups, Friedman two-way analysis of 
variance (ANOVA) by ranks was performed. The different normalised ΔSUVs were 
compared using a threshold for significant difference of 20%. In studies comparing the test-
retest characteristics of FDG-uptake a test-to-test variability of 15-20% is found, meaning 140 
that a change in SUV between ~-20% to ~+20% is within the reproducibility limits of the 
test [17,18]. 
Overall survival (OS) and progression free survival (PFS) served as the standard of 
reference. Death of any cause was defined as an event in OS analysis. Survival time was 
defined as the time between first FDG-PET and event (death or progression). Kaplan-Meier 145 
analysis was performed to determine median survival. Dichotomisation was performed at 
the median metabolic response and strata were compared by the log rank test. Cox’s 
proportional hazards model was used to assess the predictive value of response evaluation 
with FDG-PET, as expressed in the ΔSUVs between the FDG-PET at baseline and follow-
up. Hazard ratios (HR) are presented with their 95%-confidence interval (CI, Wald’s χ2 150 
test) together with the ratio in mean survival (median ratio). Finally, to investigate how a 
prognosis-driven threshold (as contrast to metabolic response-driven threshold) might 
prove of additional value, a cut-off for ΔSUV was determined for which >90% of the 
patients show 1-year OS. 
Analysis was performed with the Statistical Package for Social Sciences (SPSS®) 155 
version 16.0.2 for Mac (SPSS Inc, Chicago, Illinois, USA) and GraphPad Prism 5.0a for 
Mac (GraphPad Software Inc, La Jolla, California, USA). Statistical tests were based on a 
two-sided significance level and the level of significance was set at p=0.05 for all tests. 
 
Results 160 
Patient characteristics 
One hundred and twenty consecutive eligible patients were included in this prospective 
study (61 advanced CRC, 59 NSCLC). After the baseline FDG-PET, 23 patients (13 CRC, 
10 NSCLC) were excluded for several reasons: due to technical issues (n=7), refusal to 
undergo a second FDG-PET (n=3), death before the second FDG-PET (n=3) and early 165 
discontinuation of chemotherapy due to a significant decline in performance status (n=10). 
Therefore, complete datasets of two FDG-PETs were available in 97 patients (48 CRC and 
49 NSCLC) for analysis of therapy response. Patient characteristics are summarised in table 
2. No patients were lost during follow-up. Results of survival analysis by Kaplan-Meier are 
displayed in table 3.  170 
In CRC, mean bodyweight was significantly higher at the baseline scan compared 
to the follow-up scan (78.3kg versus 77.1kg, p=0.012, individual range -15 to +3kg). Mean 
serum glucose (5.4mmol·L-1 versus 5.5mmol·L-1, p=0.115, individual range -1.1 to +3.2 
mmol·L-1) and injected dose (199MBq versus 204MBq, p=0.592) did not differ. In NSCLC, 
mean serum glucose was significantly higher at the baseline scan compared to the follow-175 
up scan (5.5mmol·L-1 versus 5.2mmol·L-1, p=0.029, individual range -2.0 to +2.6 mmol·L-
1). Mean bodyweight (73.9kg versus 73.7 kg, p=0.637, individual range -9.0 to +10 kg) and 
injected dose (202MBq versus 212MBq, p=0.215) did not differ. 
 
Semi-quantitative changes in FDG uptake 180 
Median interval between baseline and follow-up FDG-PET was 8.9 weeks (IQR 7.0-9.6) in 
the CRC-group and 7.0 weeks (IQR 5.9-8.6) in the NSCLC-group. Box-and-whisker plots 
of ΔSUVs are displayed in figure 1. In both CRC and NSCLC the decline in median of all 
four SUVs between first and second FDG-PET was statistically significant (p<0.001). No 
significant differences between the four compared ΔSUVs could be found in CRC 185 
(p=0.143) and NSCLC (p=0.059). 
In CRC differences in metabolic response between ΔSUVLBM, ΔSUVBSA and 
ΔSUVBW+G compared to ΔSUVBW was more than the reproducibility limit in 1, 0 and 5 of 
48 cases respectively. In NSCLC this was 0, 0 and 5 of 49 cases respectively.  
 190 
Prediction of survival by FDG-PET 
Cox’s proportional hazards model for CRC and NSCLC showed high predictive 
significance for OS and PFS for all four ΔSUV normalisations between baseline and 
follow-up FDG-PET (table 4).  
To assess for predictive ability of the four normalisation methods of metabolic 195 
treatment response as to OS and PFS, patients were dichotomised to the median ΔSUV. 
Results are displayed in table 5. 
In CRC using a cut-off for ΔSUV of -33% for BW, LBM and BSA and -22% for 
BW+G separated patients who had 90% 1-year OS from those with lower OS rates. In 
NSCLC these cut-offs were -56% for BW, -57% for LBM and BSA and -53% for BW+G. 200 
The group defined as metabolic responders consisted of 24-31% of the patients. In contrast 
to CRC, in NSCLC these numbers were very different from the medians (~-37%). This 
prognosis-driven dichotomisation for NSCLC for OS resulted in median ratios of 0.28 (HR 
2.8, log rank p=0.001) for ΔSUVBW and ΔSUVBW+G and 0.22 (HR 3.1, log rank p<0.001) 
for ΔSUVLBM and for ΔSUVBSA. 205 
 
Discussion 
In this study, we showed for the first time that the method for SUV-normalisation does not 
influence the predictive value of FDG-PET in CRC and NSCLC in chemotherapy response 
monitoring. The predictive value of FDG-PET for CRC [6] and NSCLC [19-25] has been 210 
studied extensively and is an established predictor for survival. Chemotherapy response 
monitoring in CRC was performed by different groups, all using absolute [10,26,27] or 
relative [11] SUVBW differences as a measure for change in metabolic activity. In NSCLC, 
relative changes in SUV as result of therapy have been observed in numerous studies. Some 
used BW normalised SUV [12,28-30], others used normalisation by BSA and serum 215 
glucose [9]. However, for metabolic response assessment none so far investigated which of 
the different normalisations is optimal as compared to overall and progression free survival.  
In both CRC and NSCLC, all four normalised SUVs showed a significant decrease 
between baseline and follow-up FDG-PET. Although it was shown that bodyweight (in 
CRC) and serum glucose (in NSCLC), the major factors for normalisation of SUV, were 220 
significantly different between both baseline and follow-up scan, we did not find mutual 
differences between the four ΔSUV-normalisations. This suggests that there is no 
preference for either any of the four normalisations in SUV when therapy response is 
measured by relative changes in SUVs between baseline and follow-up FDG-PET. 
Krak et al. [17] describe that standard deviation between two consecutive scans 225 
(made on 2 consecutive days) was 11% using the same definition of ROI as in this study. 
Therefore SUVs on 2 consecutive days may vary ~±20% due to reproducibility limits of the 
test. Using this as a cut-off for a significant different ΔSUV between the 2 normalisations 
we found that especially in ΔSUVBW+G more often a change in metabolism was found 
>20% different from ΔSUVBW. The addition of the extra variable plasma glucose level 230 
caused in 5 CRC and 5 NSCLC patients a highly different conclusion about treatment 
response. To verify the clinical significance of this different magnitude of metabolic 
response, it was related to survival. 
Choosing a cut-off value of metabolic response for 90% 1-year OS, led to a 
median survival ratio of 0.22-0.28 for metabolic non-responders versus responders. In CRC 235 
the effect of abovementioned cut-off was similar to the median SUV change (and thus 
selects ~50% best responders). 
We observed higher hazard ratios for NSCLC than CRC. This suggests that similar 
reduction in SUV in CRC has less effect on patient overall survival than in NSCLC. This 
may be caused by biological differences and differences in chemosensitivity of both types 240 
of cancer. However, changes in glucose metabolic rate, are not only dependent on 
biological behaviour of the tumour to the given treatment, but are also dependent on the 
treatment protocol and the timing of follow-up scanning. Both these biological differences 
and variation in treatment and follow-up protocol hinder determination of optimal cut-offs. 
Therefore standardisation of response measurement protocols are necessary and cut-offs 245 
should be dependent of tumour-type, antitumour treatment and timing of evaluation. 
Earlier publications [11,12] showed that SUV is a sufficiently robust measure for 
treatment response monitoring and can reliably replace more complex, invasive and time-
consuming measures such as Patlak analysis which determines glucose metabolic rate 
(MRglc). Apart from being a less time-consuming method, SUV can be calculated from a 250 
whole-body FDG-PET study including all metastatic lesions. Furthermore, no input 
function is required for SUV-determination. The advantage of relative SUV-determination 
compared to absolute SUVs, however, is that it is easier to combine data from different 
studies because they are less sensitive to introduction of errors due to noise, image 
resolution and ROI-definition compared to absolute SUVs [17,31-33]. If the patient is 255 
scanned in the same hospital on the same scanner, some scanner related factors and patient 
related factors can be ignored [33]. 
Different normalisation methods for absolute SUV values have been addressed by 
others [34-38], reporting varying results. Some have shown that SUV corrected for BSA 
proved to be more accurate, in adult [34] and paediatric [38] patients, compared to the gold 260 
standard MRglc. It was suggested that normalisation is necessary because of variability in 
SUV due to body composition and habitus as well as plasma glucose [32,39]. Menda et al. 
[36] observed no advantage of any SUV correction for accuracy of diagnosis of pulmonary 
malignancy. In contrast with our study, these studies did not address therapy response, and 
therefore did not take into consideration the measurement of relative changes in SUV. 265 
Krak et al. [35] compared different normalisations for relative SUV change in 20 
women with locally advanced or metastasised breast cancer with the golden standard of 
non-linear regression after 1, 2 or 6 courses of chemotherapy. They concluded that of the 
investigated normalisation methods, relative change of SUV corrected for both LBM and 
glucose showed highest correlation with relative change in glucose metabolic rate as 270 
calculated by non-linear regression. This study did not correlate SUV corrections with 
clinical outcome parameters such as patient survival. 
Stahl et al. [37] compared histological response in 43 patients with locally 
advanced gastric carcinomas with the same four normalisations for relative SUV change as 
in our study, between baseline and follow-up FDG-PET (after 2 weeks, during first cycle of 275 
platinum-based chemotherapy). They, too, concluded that no normalisation method of 
ΔSUVs has an advantage for response prediction and that the theoretical benefits of the 
measures to reduce the dependency of the SUV on BW or plasma glucose do not translate 
into a detectable clinical benefit.  
Our study showed no preference of any SUV-normalisation in therapy response 280 
monitoring in CRC and NSCLC. This could be caused by the fact that SUVs used in 
therapy response monitoring are compared in individual patients and not between different 
patients. It can be easily derived that an increase in bodyweight alone of 10%, increases 
ΔSUVBW and ΔSUVBW+G by 10%, ΔSUVBSA by 4.1% (=[1.10]0.425-1) and has no effect on 
ΔSUVLBM. An increase of plasma glucose alone of 10% increases ΔSUVBW+G by 10%. The 285 
effect of chemotherapy and disease on body composition seems to be relatively small. 
Therefore it is possible to select the SUV, which is simplest, without introduction of extra 
parameters like bodyweight, length or serum glucose. All these parameters necessitate 
calibration and may for that reason potentially introduce extra uncertainties. Moreover, 
simplifying FDG-PET methodology in therapy response monitoring could facilitate its 290 
introduction in routine clinical practice.  
The variety of applied analytical methods is vast, which hampers multicentre 
research. Clear methods for standardisation of acquisition, reconstruction, ROI-
determination and SUV-normalisation need to be determined [33]. In fact, methodology of 
metabolic response evaluation needs to be standardised in evidence based multidisciplinary 295 
international guidelines. This has been attempted previously by the European Organisation 
for Research and Treatment of Cancer (EORTC) [40] and the National Cancer Institute 
(NCI) [15]. However, they provide consensus-based recommendations, rather than advice-
based on scientific proof. Evidence-based guidelines would be of utmost importance for the 
interpretation and comparison of multicentre trials.  300 
 
Conclusion 
In chemotherapy response evaluation in both CRC and patients with NSCLC, relative SUV 
changes in FDG-PET have high predictive value for patient survival. Using relative 
changes in tumour FDG-uptake for a patient, no normalisation for body habitus in SUV-305 
calculation seems superior, since all perform equally well for prediction of survival in both 
types of cancer. Therefore theoretical advantages of one normalisation method over 
another, do not translate into clinical relevant changes. This finding in combination with the 
fact that relative (rather than absolute) changes are less dependent of quantitative PET 
acquisition protocols [17,31], will facilitate determination of response to therapy. This 310 
could be a step towards standardizing the results of therapy monitoring which might be 
used for pooling of data in multicentre trials. Moreover, it may enable integration of 
metabolic response measurement in the development of clinical guidelines by giving 
evidence-based definitions of partial response, stable disease and progressive disease for 
different cancer types. 315 
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 Tables 
 
SUV normalisation: Formula: 
SUVBW (bodyweight) SUVBW = Ct·(I·BW-1)-1 
SUVLBM (lean body mass) SUVLBM = Ct·(I·LBM-1)-1 
Male: LBM= 48.0+1.06·(h-152) 
Female: LBM=45.5+0.91·(h-152) 
SUVBSA (body surface area) SUVBSA = Ct·(I·BSA-1)-1 
BSA= 0.007184·BW0.425·h0.725 
SUVBW+G (bodyweight and plasma glucose) SUVBW+G = SUVBW·PG 
Table 1: Four SUV normalisations evaluated in this study. Ct: tissue concentration 
[kBq.ml-1]; I: injected dose [MBq]; BW: bodyweight [kg]; LBM: lean body mass [kg]; 
h: height [cm]; BSA: body surface area [m2]; PG: plasma glucose [mmol.L-1]. 
 
Characteristics: CRC: NSCLC: 
Demography: 
Number of patients 
Mean age (year) [range] 
Men (%) 
 
48 
61.0 [44.7-78.9] 
73 
 
49 
59.6 [38.5-76.2] 
74 
Location of metastases (%): 
Liver 
Lung 
Lymph nodes 
Bone 
Brain 
Adrenals 
Other 
None 
 
86 
29 
8 
4 
- 
- 
- 
- 
 
14 
37 
67 
12 
16 
12 
10 
6 
Histology (%): 
Adenocarcinoma 
Squamous cell carcinoma 
Large cell carcinoma 
Mucinous adenocarcinoma 
Bronchoalveolar cell carcinoma 
Clear cell carcinoma 
 
94 
- 
- 
6 
- 
- 
 
45 
43 
8 
- 
2 
2 
Tumour grade (%): 
Undifferentiated: 
Very poor 
Poor 
Intermediate 
 
2 
4 
10 
60 
 
- 
27 
12 
12 
Well 
Mucinous 
Unspecified 
4 
- 
19 
2 
2 
45 
Tumour stage (%): 
I 
II 
III 
IV 
 
- 
- 
- 
100 
 
2 (B) 
2 (A) 
16 (A), 20 (B) 
59 
Table 2: Patient characteristics. CRC: colorectal carcinoma; NSCLC: non-small cell 
lung carcinoma; N/a: not applicable. 
  Event-free  
n [%] 
Median [CI]  
(weeks) 
1 year [CI]  
(%) 
2 year[CI]  
(%) 
3 year[CI] 
(%) 
CRC: 
Overall survival 
Progression free survival 
 
7 [15] 
1 [2] 
 
85 [70-100] 
24 [19-29] 
 
77 [65-89] 
17 [6-27] 
 
34 [21-48] 
4 [0-10] 
 
14 [3-25] 
2 [0-6] 
NSCLC: 
Overall survival  
Progression free survival 
 
7 [14] 
4 [8] 
 
62 [42-82] 
30 [17-42] 
 
57 [43-71] 
30 [17-42] 
 
39 [25-53] 
19 [8-30] 
 
22 [10-34] 
10 [1-18] 
Table 3: Results of follow-up. CRC: colorectal carcinoma; NSCLC: non-small cell lung carcinoma; CI: 95%-
confidence interval. 
  Overall Survival: Progression Free Survival: 
Hazard  
Ratio 
CI Hazard  
Ratio 
CI 
CRC:     
ΔSUVBW 
ΔSUVLBM 
ΔSUVBSA 
ΔSUVBW+G 
 
1.16† 
1.14† 
1.15† 
1.14† 
1.04-1.29 
1.04-1.26 
1.04-1.27 
1.03-1.24 
1.15† 
1.15† 
1.15† 
1.15† 
1.04-1.28 
1.04-1.27 
1.04-1.27 
1.04-1.26 
NSCLC:     
ΔSUVBW 
ΔSUVLBM 
ΔSUVBSA 
ΔSUVBW+G 
1.12† 
1.10† 
1.10† 
1.13† 
 
1.03-1.20 
1.03-1.17 
1.03-1.18 
1.04-1.21 
 
1.12† 
1.10† 
1.12† 
1.12† 
 
1.04-1.20 
1.04-1.18 
1.04-1.18 
1.03-1.20 
 
Table 4: Results of univariate Cox proportional hazards regression 
analysis for overall and progression free survival using ΔSUVs between 
the scan at baseline and evaluation. ΔSUV: relative change in 
Standardised uptake value between baseline and follow-up; CRC: 
colorectal carcinoma; NSCLC: non-small cell lung carcinoma; BW: 
normalisation for bodyweight; LBM: normalisation for lean body mass; 
BSA: normalised for body surface area; BW+G: normalised for 
bodyweight and plasma glucose; CI: 95%-confidence interval; *per ten 
percent change; †Significant by Wald’s χ2 test. 
 
 Overall Survival: Progression Free Survival: 
Median 
Ratio 
Hazard  
Ratio 
CI Median 
Ratio 
Hazard  
Ratio 
CI 
CRC:       
ΔSUVBW 
ΔSUVLBM 
ΔSUVBSA 
ΔSUVBW+G 
 
0.60 
0.82 
0.60 
0.60 
1.95† 
1.33 
1.95† 
2.48† 
1.03-3.69 
0.71-2.47 
1.03-3.69 
1.26-4.89 
0.59 
0.65 
0.59 
0.52 
1.92† 
1.57 
1.92† 
2.08† 
1.07-3.44 
0.88-2.80 
1.07-3.44 
1.16-3.74 
NSCLC:       
ΔSUVBW 
ΔSUVLBM 
ΔSUVBSA 
ΔSUVBW+G 
 
0.48 
0.48 
0.48 
0.70 
2.12† 
2.12† 
2.12† 
1.48 
1.14-3.92 
1.14-3.92 
1.14-3.92 
0.80-2.74 
0.37 
0.37 
0.37 
0.45 
2.97† 
2.97† 
2.97† 
1.60 
1.56-5.66 
1.56-5.66 
1.56-5.66 
0.89-2.88 
Table 5: Results of univariate Kaplan-Meier analysis for overall and progression free 
survival using ΔSUVs between the scan at baseline and evaluation dichotomised at their 
median for response or non-response. ΔSUV: relative change in Standardised uptake value 
between baseline and follow-up scan; CRC: Colorectal carcinoma; NSCLC: Non-small 
cell lung carcinoma; BW: normalisation for bodyweight; LBM: normalisation for lean 
body mass; BSA: normalised for body surface area; BW+G: normalised for bodyweight 
and plasma glucose; CI: 95%-Confidence Interval; †Significant by log rank test. 
 Figures 
 
Figure 1: Box-and-whisker plots of four normalisations for percentage change in 
Standardised Uptake Value between baseline and follow-up 18F-2-fluoro-2-deoxy-D-
glucose positron emission tomography. The boxes are constructed by the mean, first and 
third quartiles. The whiskers extend 1.5 times the interquartile range above and below the 
25th and 75th percentiles. Outliers are displayed as open circles. CRC: colorectal 
carcinoma; NSCLC: non-small cell lung carcinoma. 
 
